Stanford researchers have developed novel technology that combines AAVMYO, a muscle cell targeting viral vector, with CRISPR base editors to achieve targeted gene repair, showcasing over 70% correction of hereditary mutations in cardiomyocytes.
Researchers in the Stanford Genome Technology Center have developed a robust, high-throughput, high-efficiency functional genomics platform to generate precisely edited genome variant libraries and then readily isolate and identify thousands of individual strains en masse